OCULAR THERAPEUTIX, INC

Ocular Therapeutix announced its participation in several upcoming scientific and investor conferences in July 2026. The company will present at the 9th Annual OIS Retina Innovation Summit and the ASRS 44th Annual Meeting, where it will share efficacy and safety results from the Phase 3 SOL-1 trial for OTX-TKI in neovascular age-related macular degeneration. Additionally, the Executive Chairman, President and CEO will engage in a fireside chat at the HC Wainwright 6th Annual Ophthalmology Virtual Conference.

Ocular Therapeutix announced FDA alignment for its AXPAXLI New Drug Application (NDA) in wet Age-related Macular Degeneration (AMD), with submission planned for Q4 2026. The NDA will be based on SOL-1 Week 52 efficacy and safety data, combined with interim SOL-R safety data, aiming to reach over 300 patients of safety data. The company also streamlined its diabetic retinopathy program to prioritize a single Phase 3 trial, HELIOS-3, evaluating Q12M dosing of AXPAXLI. The SOL-R trial's efficacy data is no longer part of the initial NDA submission, allowing Ocular to extend masking and evaluate new secondary endpoints, including superiority over aflibercept (8mg) at Week 96, with topline results now expected in Q1 2028.

Ocular Therapeutix, Inc. announced the appointment of Jason Robins as its permanent Chief Financial Officer, effective June 10, 2026. His compensation package includes an annual base salary of $535,100, a target annual cash bonus of 45% of his base, and equity awards comprising 14,024 stock options and 15,441 restricted stock units. Additionally, stockholders approved an amendment to the 2021 Stock Incentive Plan, increasing the number of shares issuable by 10,000,000. At the 2026 Annual Meeting, stockholders also re-elected two Class III directors and approved executive compensation on an advisory basis.

Ocular Therapeutix announced its participation in Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas. The company will present multiple updates on its investigational product candidate, OTX-TKI (AXPAXLI), for retinal diseases such as wet age-related macular degeneration (nAMD) and nonproliferative diabetic retinopathy (NPDR). Key presentations include efficacy and safety outcomes from the SOL-1 Phase 3 trial and an update on the HELIOS program, alongside fireside chats and a panel discussion featuring company leadership.

Ocular Therapeutix, Inc. announced the appointment of Ms. Amy Ricca as its new SVP, Head of HR, effective May 11, 2026. As an inducement for her employment, the company granted Ms. Ricca a non-statutory stock option award to purchase up to 75,000 shares of common stock and restricted stock unit awards for 25,000 shares. The stock option has an exercise price of $9.28 per share and vests over four years, while the RSUs vest over three years.

Ocular Therapeutix, Inc. announced the grant of inducement awards to twelve newly hired non-executive employees. These awards, made under the Company's 2019 Inducement Stock Incentive Plan, consist of non-statutory stock options to purchase 127,650 shares and restricted stock units representing 41,550 shares of common stock. The stock options have an exercise price of $9.71 per share and vest over four years, while the restricted stock units vest over three years.

Ocular Therapeutix reported a significant increase in net loss for the first quarter of 2026, reaching $(88.6) million, up from $(64.1) million in the prior year. This was primarily driven by a substantial rise in research and development expenses, which climbed to $66.2 million. Despite a slight increase in total revenue to $10.8 million, the company experienced a higher net cash outflow from operating activities, though it maintains a cash and cash equivalents balance of $666.7 million, expected to fund operations for at least the next 12 months.

Ocular Therapeutix reported its first quarter 2026 financial results and significant business highlights, primarily driven by positive Phase 3 SOL-1 results for AXPAXLI in wet AMD. The trial demonstrated superior visual outcomes and sustained disease control, leading to accelerated commercial preparedness and plans for an NDA submission. The company reported a Q1 2026 net loss of $(88.6) million, with a strong cash balance of $666.7 million providing a runway into 2028.

Ocular Therapeutix, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026. Key proposals include the election of two Class III directors and an amendment to increase shares under the 2021 Stock Incentive Plan by 10,000,000. The company also highlighted a transformative 2025, with significant progress in advancing AXPAXLI Phase 3 programs for wet AMD and diabetic retinal disease, and the announcement of positive superiority data from the SOL-1 Phase 3 trial in February 2026. A successful $475 million fundraising in Fall 2025 extended the cash runway into 2028.

Ocular Therapeutix, Inc. announced it will host a conference call and webcast on Tuesday, May 5, 2026, at 8:00 AM ET. The event will cover the company's recent business progress and financial results for the first quarter ended March 31, 2026. Investors can access the call via provided dial-in numbers and a conference ID, or through a live and archived webcast on the company's investor relations website.